CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control over editorial content. More information is available here »

CGRP mAb response rate increases over three years Study reassures on CGRP mAb cardiovascular safety Modest weight loss confirmed with atogepant Spotlight on anti-CGRP therapies in 2024 Targeting CGRP and PACAP-38 in migraine SPACE trial: Fremanezumab reduces migraine days in children Restarting CGRP mAbs restores efficacy after drug holiday Gepant efficacy in menstrual migraine

Galcanezumab

Galcanezumab

The CGRP monoclonal antibody, Emgality (galcanezumab), was approved for the prevention of migraine in adults in September 2018 and, in June 2019, became the first and only anti-CGRP therapy to be approved for the prevention of episodic cluster headache in adults. These approvals were supported by data including the results of the EVOLVE 1 and 2 trials in episodic migraine, the REGAIN trial in chronic migraine and a Phase 3 study in cluster headache. The CONQUER trial investigated the efficacy of galcanezumab in patients with migraine who had failed on 2-4 previous preventive therapies.

Download slideset »

« back to Slides

Educational Partners and Supporters

This program is funded in part via an independent educational grant from AbbVie.

Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.

Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2025 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach | Educational Partners and Supporters |